-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Neutral on Lyell Immunopharma, Raises Price Target to $20

Benzinga·11/24/2025 12:53:43
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Lyell Immunopharma (NASDAQ:LYEL) with a Neutral and raises the price target from $10 to $20.